- Report
- February 2024
- 204 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- August 2018
- 133 Pages
Global
From €3079EUR$3,185USD£2,645GBP
€4399EUR$4,550USD£3,778GBP
- Report
- April 2023
- 117 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- April 2023
- 450 Pages
Global
From €3142EUR$3,250USD£2,699GBP
- Report
- November 2020
- 49 Pages
Global
€1274EUR$1,318USD£1,094GBP
Onivyde is a market of drugs used to treat lung cancer. It is a type of chemotherapy drug that is used to treat advanced stages of the disease. Onivyde works by targeting and destroying cancer cells, while also helping to reduce the side effects of other chemotherapy drugs. It is typically used in combination with other chemotherapy drugs, such as cisplatin and gemcitabine. Onivyde is also used to treat metastatic non-small cell lung cancer, which is a type of cancer that has spread to other parts of the body.
Onivyde is a relatively new drug, having been approved by the FDA in 2015. It is currently available in the United States, Canada, and Europe. It is also being studied in clinical trials for other types of cancer, such as pancreatic cancer.
Some companies in the Onivyde market include Merrimack Pharmaceuticals, Ipsen, and Eisai. Merrimack Pharmaceuticals is the developer of Onivyde, while Ipsen and Eisai are responsible for marketing and distributing the drug. Show Less Read more